A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.

Fiche publication

Date publication

juin 2017

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MENEVEAU Nathalie , Pr PIVOT Xavier , Dr VERNEREY Dewi , Dr MOUGIN-GUILLAUME Fabienne , Dr JACQUINOT Quentin

Tous les auteurs :
Jacquinot Q, Meneveau N, Chatot M, Bonnetain F, Degano B, Bouhaddi M, Dumoulin G, Vernerey D, Pivot X, Mougin F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28629338

Résumé

The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor prognosis. Trastuzumab improves overall survival but is associated with cardiotoxicity, especially a decline in left ventricular ejection fraction (LVEF). In addition, chemotherapy and radiotherapy increase fatigue and pain, decrease physical capacity and health-related quality of life. To date, no study has evaluated the benefits of physical activity on the side effects of treatment in patients with HER2 positive breast cancer. The aim of this study is to evaluate the impact of 3 months' exercise intervention on myocardial function and in particular on the rate of cardiotoxicity.